GIST Cancer UK  is partnering with Sarcoma UK  in providing support for research projects aimed at better understanding of sarcomas and their treatment.  You can find further details on the Sarcoma UK website.

The fascinating and informative sessions from the recent Cardiff conference can now be viewed at the Patient Meetings section of the website.

Our spring newsletter is now out with information on what’s going on in the GIST world – Register with us if you want to make sure that you receive this on a regular basis.

Some GISTS develop resistance to standard drug treatment (e.g. imatinib, sunitinib, regorafenib, ripritinib).  A new drug is being trialed to prevent the emergence of sub-clones or to treat TKI resistant GISTs.  This trial is being coordinated by Professor Robin Jones at the Royal Marsden Hospital in London.

The PEAK trial is now open at various UK centres and may be relevant for those for whom imatinib is not working.  You can access further details from the clinical trials section of this site.

The GCUK Board would like to extend their appreciation to everyone for their work during the past year in supporting the charity, fellow patients and family, and wish you a merry festive season and best wishes for 2024.

Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors (GIST), according to research presented at the ESMO Congress 2023.

The Autumn Newsletter has arrived with updates on a range of GIST-related matters.  GIST Cancer UK October Newsletter

Videos of the sessions at the October 2023 Patient Carer meeting held in Leeds are now available on the Patient Meetings 2023 section of this site.

The outcome of the recent Intrigue study which compared the effectiveness and side effects associated with these drugs can be found here